The firm gained approval for one acquired program, the ROS1 inhibitor Jideytro, and is expecting another approval for the ALK inhibitor neladalkib this year.
NEW YORK – The European Medicines Agency has given the green light to an investigator-initiated trial of Lantern Pharma's lead drug candidate LP-184 (zirdafulven) for advanced, recurrent bladder ...
The company closed an upsized IPO and concurrent private placement to Sanofi, proceeds of which will fund its pipeline of CRISPR-based medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results